Lyamine Hedjazi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Lyamine Hedjazi has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Gilles Favre
INSERM, Centre de Recherche en Cancérologie de Toulouse, CRCT UMR-1037, Toulouse, France; Institut Claudius Regaud, IUCT-Oncopole, Laboratoire de Biologie Médicale Oncologique, Toulouse, France; University of Toulouse III (Paul Sabatier), Toulouse, France
2 shared publications Florence Dalenc
Institut Claudius Regaud
1 shared publication- Florence Dalenc
Dendris SAS, 8 Rue de Cugnaux, 31300, Toulouse, France.
1 shared publication Joseph Aguilar-Martin
CNRS
1 shared publication- Joseph Aguilar-Martin
Université de Toulouse, LAAS-CNRS, 7, Avenue du Colonel Roche, 31077 Toulouse, France
1 shared publication Laurène Despenes
1 shared publication
Latest Publications
- 30 July 2013
- Published by SAGE Publications in Journal of Computational Biology
- Vol. 20 (8) , 610-620
Symbolic Data Analysis to Defy Low Signal-to-Noise Ratio in Microarray Data for Breast Cancer Prognosis
Microarray profiling has recently generated the hope to gain new insights into breast cancer biology and thereby improve the performance of current prognostic tools. However, it also poses several serious challenges to classical data analysis techniques related to the characteristics of resulting data, mainly high dimensionality and low signal-to-noise ratio. Despite the tremendous research work performed to handle the first challenge in the feature selection framework, very little attention has been directed to address the second one. We propose in this article to address both issues simultaneously based on symbolic data analysis capabilities in order to derive more accurate genetic marker–based prognostic models. In particular, interval data representation is employed to model various uncertainties in microarray measurements. A recent feature selection algorithm that handles symbolic interval data is used then to derive a genetic signature. The predictive value of the derived signature is then assessed by following a rigorous experimental setup and compared with existing prognostic approaches in terms of predictive performance and estimated survival probability. It is shown that the derived signature (GenSym) performs significantly better than other prognostic models, including the 70-gene signature, St. Gallen, and National Institutes of Health criteria.
- 30 July 2013
- Published by SAGE Publications in Journal of Computational Biology
- Vol. 20 (8) , 610-620
Symbolic Data Analysis to Defy Low Signal-to-Noise Ratio in Microarray Data for Breast Cancer Prognosis
Microarray profiling has recently generated the hope to gain new insights into breast cancer biology and thereby improve the performance of current prognostic tools. However, it also poses several serious challenges to classical data analysis techniques related to the characteristics of resulting data, mainly high dimensionality and low signal-to-noise ratio. Despite the tremendous research work performed to handle the first challenge in the feature selection framework, very little attention has been directed to address the second one. We propose in this article to address both issues simultaneously based on symbolic data analysis capabilities in order to derive more accurate genetic marker–based prognostic models. In particular, interval data representation is employed to model various uncertainties in microarray measurements. A recent feature selection algorithm that handles symbolic interval data is used then to derive a genetic signature. The predictive value of the derived signature is then assessed by following a rigorous experimental setup and compared with existing prognostic approaches in terms of predictive performance and estimated survival probability. It is shown that the derived signature (GenSym) performs significantly better than other prognostic models, including the 70-gene signature, St. Gallen, and National Institutes of Health criteria.